Strong growth in the first half of 2022 (German)

Berlin, August 11, 2022 – Medios AG ^

DGAP-News: Medios AG / Keywords: Semi-annual report / Semi-annual results

Medios AG continues its record course: Strong growth in the first half of 2022

November 8, 2022 / 07:37

The best jobs of the day

Find the best job offers now and
be notified by e-mail.

The issuer / publisher is responsible for the content of the application.

————————————————– —————————————

press release

Medios AG continues its record course: Strong growth in the first half of 2022

* Sales increased by 25% – Strong inorganic and organic


* Profit margins improved significantly and sustained sixth

Record for a quarter in a row

* Cash flows from operating activities in both Q2 2022 and Q1

H1 2022 positive

* Guidelines for fiscal year 2022 despite the ongoing global trend

Uncertainties confirmed, expected sales will be in the upper range of the forecast

Berlin, August 11, 2022 – Medios AG (“Medios”), leading supplier

by Specialty Pharma Solutions in Germany, is dynamically developing

continued in the first half of 2022. The Group’s sales increased during this period

from January to June compared to the same period last year, by 24.8% to 792.2

million euros (previous year: 634.9 million euros). Pre1 EBITDA grew disproportionately

55.9% to EUR 28.5 million (previous year: EUR 18.3 million) with a correspondingly higher

margin of 3.6% (previous year: 2.9%). Sales and earnings thus reached new heights

maximum values. Both operating segments had an impact on both revenues and

contribute to an increase in earnings. Based on strong business development

Medios has confirmed its sales and profit forecast for the full year 2022.

The company expects sales to hit the high end of the range

EUR 1.45 – 1.6 billion capacity was transferred.

The sales growth of the Medios Group by approximately 25% in the first half of the year increased

a large part of inorganic growth through integration

NewCo Pharma Group (16 percentage points). 9 percentage points were settled

organic growth. With the acquisition of NewCo Pharma Group Medios

in particular, the segment of patient-specific therapies has been strengthened.

In the first half of 2022, cash flow from operating activities amounted to 10

million and was influenced by strategic stockpiling. Down

Therefore, Medios expects the second half of 2022 to be correspondingly positive

Impact on cash flow from decreases in inventories.

Matthias Gärtner, CEO of Medios AG: “With the sixth

A record quarter in a row is the strong growth of the Medios Group

uninterrupted. In addition to our constant organic growth, we move on

acquisition of NewCo-Pharma-Group again also inorganic

a lot has grown. This not only strengthens our segment

Patient-specific therapies that increase ours at the same time

The profit margin is clear and stable. I am very proud to be together

with my management colleagues and the entire Medios team, ours

A society so successful and balanced at this difficult time


The production of personalized medicinal products will be

The integration of NewCo Pharma Group has almost tripled and

Expand fiscal year 2022 to over 320,000 productions. Additionally

recent acquisitions enable further acquisitions

Synergy and cross-selling effects – incl. in shopping and in

production. The network of specialized partner pharmacies has also grown

increased to over 600 as a result of the merger with NewCo Pharma Group.

In the first half of 2022, Medios will also make further progress in implementation

innovative digital trading platform for individualized

the drug “mediosconnect” was reached. He’s in five states now

available. As users, over 30 new practices could be acquired

and the number of orders placed via “mediosconnect”.

increased by about 20%.

With effect from June 20, 2022, Medios’ participation has been re-included in

Choose the Deutsche Börse SDAX index included in the price. It was done under

unplanned change in SDAX and TecDAX indices, which

Deutsche Börse announced shortly before. The SDAX covers 70

the largest companies in Prime Standard by market capitalization

below MDAX.

On August 1, the company also announced that

Supervisory Board of Medios AG and CEO Matthias

Gärtner on an early extension of the existing contract with the management board

until January 31, 2025 Matthias Gärtner has been with us since September

2015 Member of the Management Board, and from January 2021, President of the Management Board.

Medios therefore relies on continuity and stability in the governing body


Positive outlook for 2022 confirmed

Medios AG confirms the forecast for the financial year 2022 despite

ongoing global uncertainty. The company’s sales have been growing since

Reaching the upper limit of the range of EUR 1.45 – 1.6 billion

(An increase of up to 17.9% compared to 2021). When EBITDA pre1 becomes

the range of EUR 52-58 million is still expected (an increase of 35.3%

up to 50.9% compared to 2021). Another limitation is currently

due to the mentioned and possible global uncertainties

regulatory changes are not possible.

Key Performance Indicators (IFRS)

in EUR million H1 2022 first half 2021 in%

Group turnover 792.2 634.9 24.8

Drug supply 682.5 603.6 13.1

Patient-specific therapies 109.5 31.0 252.6

Services 0.2 0.3 -25.5

EBITDA before 1 28.5 18.3 55.9

Drug supply 17.5 15.2 14.5

Patient-specific therapies 13.2 4.0 235.1

Services -2.2 -0.9 137.6

Important dates for Medios AG in the financial year 2022:

September 20: Berenberg and Goldman Sachs Eleventh German Corporation

Conference – Munich

November 10: Quarterly report (3rd quarter and 9 months 2022)

December 7: Berenberg European Conference 2022 – Pennyhill Park, Surrey,

Great Britain

Half-yearly financial statements as at June 30, 2022 are available on the Investor website

Report website available for download.

1 EBITDA is defined as income before interest, taxes

and depreciation. Preliminary EBITDA is adjusted for special expenses for

Stock options and activities related to mergers and acquisitions.


About Medios AG

Medios AG is a leading provider of specialized pharmaceutical solutions in

Germany. As a competence and expert partner, Medios covers all the essentials

Supply chain aspects in this area: from

Drug supply for the production of patient-specific therapies

including blister. The emphasis is on the optimum

Patient care through specialized pharmacies.

Medios AG is the first specialist pharmacy listed on the stock exchange in Germany

and are listed in the SDAX selection index. Actions (ISIN:

DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange

(Main Standard).


Claudia Nickolas

Investor and Public Relations Director, ESG Communications

Medios AG

Heidestrasse 9 | 10557 Berlin

T +49 30 232 566 800

[email protected]

Anna Hoffken

Senior Consultant Investor & Public Relations

Kirchhoff Consult AG

Borselstraße 20 | 22765 Hamburg

T +49 40 609 186 34

[email protected]


This press release contains forward-looking statements which involve risks and

subject to uncertainty. Future results may vary considerably

differ from the currently expected results due to

various risk factors and uncertainties, such as:

changes in the business, economic and competitive situation,

currency fluctuations, uncertainty about litigation or

investigative procedures and the availability of resources.

————————————————– —————————————

November 8, 2022 publication of corporate news / financial announcement,

provided by DGAP – EQS Group AG service.

The issuer / publisher is responsible for the content of the application.

DGAP’s distribution services include statutory reporting requirements,

Corporate / financial news and press releases.

Media archive at

————————————————– —————————————


Company: Medios AG

Heidestraße 9

10557 Berlin


Telephone: +49 30 232 566 – 800

Fax: +49 30 232 566 – 801

E-mail: [email protected]




Indices: SDAX

Exchanges: Regulated market in Frankfurt (Prime Standard);

Open market in Berlin, Dusseldorf, Hamburg, Hannover,

Munich, Stuttgart, Tradegate Exchange

EQS message ID: 1417747

End of news DGAP news service

————————————————– —————————————

1417747 08/11/2022


Leave a Comment